UPMC Hillman Cancer Center | Strategic Alliance Partners

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.

Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate HER2-directed bispecific antibodies in HER2-positive breast cancer, the emergence of zanidatamab as a potential treatment strategy, and the unmet medical need the agent could fill in this disease.

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Adjuvant pembrolizumab continued to showcase improved relapse-free survival over placebo in patients with resected high-risk stage II melanoma with 6 months of additional follow-up.

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer. 

Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

Following an extensive national search, Amer Zureikat, MD, FACS, has been appointed vice chair of surgery for Surgical Oncology in the Department of Surgery at UPMC and chief of Surgical Oncology at UPMC Hillman Cancer Center.

Adam M. Brufsky, MD, PhD, discusses the future role of chemotherapy in triple-negative breast cancer.

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.